Phillip Campbell is a Research Professor in the Biomedical Engineering Department and the Engineering Research Accelerator at Carnegie Mellon University. He has courtesy appointments in the Biological Sciences and the Mechanical Engineering Departments. Campbell has over 25 years of experience in multidisciplinary research with both engineers and clinicians to develop unique solutions to a wide variety of complex biomedical problems, including the development of natural-based biomaterials, implant biocompatibility, and tissue engineering. One of his overarching research themes involves understanding and engineering the cellular microenvironment from an endocrine point of view, both in vitro and in vivo. The study encompasses growth factor interstitial transport, interactions with receptors and non-receptor binding proteins, immobilization and proteolytic processing of extracellular matrix bound growth factors and other signaling molecules, and live cell and animal imaging. His research has taken advantage of biopatterned microenvironments to spatially deliver signaling molecules to spatially control cell behavior in vitro and tissue formation in vivo toward musculoskeletal, cardiac, immunological, and cancer applications.
Microneedles unlock curcumin’s therapeutic potential
Researchers engineer a hybrid system that stabilizes curcumin to target skin diseases.
3D printing ice
3D printed ice isn’t as magical as in the movie Frozen, but it has wonderful potential for biomedical engineering and advanced manufacturing.
Exosome engineering tech licensed to Coya Therapeutics
An interdisciplinary group of faculty from Carnegie Mellon has licensed a proprietary platform for bioengineering exosomes for drug delivery to Coya Therapeutics, Inc.
Collaboration shapes extracellular vesicle retention strategy
Phil Campbell and Charlie Ren present a strategy to spatially control extracellular vesicles and keep them resolute under controlled conditions.
CMU and Mayo Clinic to collaborate on transplant innovation
Mayo Clinic and Carnegie Mellon University announced today a research agreement to transform organ transplantation. The institutions will bioengineer innovative approaches to address current barriers in organ transplantation.
Uncovering a promising use case for exosomes
New research from Carnegie Mellon University and UPMC explores an innovative case for exosomes: delivering growth factors like bone morphogenetic proteins (BMPs) for bone healing.
Using exosomes for drug delivery
In recent years, there has been an explosion in exosome research. CMU researchers have created an “all-purpose” platform for using exosomes for drug delivery in living organisms.
3D printing the human heart
CMU researchers have published in Science a new 3D bioprinting method that brings the field of tissue engineering one step closer to being able to 3D print a full-sized, adult human heart.
College of Engineering’s Celebration of Education Awards announced
Congratulations to the College of Engineering’s 2019 recipients of the Celebration of Education Awards, which recognize individuals who exemplify excellence in teaching, advising, and mentoring.
The College of Engineering faculty award winners announced
The College of Engineering has named this year’s faculty award winners, selected by the College of Engineering Faculty Awards Committee. Congratulations to the winners.
Homegrown biotech firm finds new home on South Side
Carmell Therapeutic, a biosurgical technology company focused on the development and commercialization of innovative plasma-based bioactive materials, is relocating to a manufacturing facility in Pittsburgh’s South Side.